FindTrial
Sign In

Evaluation of gene expression, methylation and secretory level of cytokines and inflammatory chemokines in COPD patients receiving nanocurcumin supplementation compared with patients receiving placebo

Evaluation of gene expression, methylation and secretory level of cytokines and inflammatory chemokines in COPD patients receiving nanocurcumin supplementation compared with patients receiving placebo

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200324046851N2
Enrollment
30
Registered
2022-02-22
Start date
2022-04-03
Completion date
Unknown
Last updated
2022-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease (COPD). Other chronic obstructive pulmonary disease

Interventions

Intervention 1: Intervention group: Nanocurcumin recipient.From 30 patients with COPD receiving 80 mg of nanocurcumin daily for 90 days before and after the intervention, 10 cc of blood containing ant

Sponsors

Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Diagnosed with COPD with stage B, C, or D according to GOLD 2019.. Age between 40-75 years old. Both genders. Smoker or less than 6 months of smoking cessation time

Exclusion criteria

Exclusion criteria: Asthma and other pulmonary-related diseases and injuries (including lung tuberculosis, restrictive lung disease, idiopathic pulmonary fibrosis, or lung cancer). Acute and/or active infection. Cancer. Patients with complex cardiovascular diseases (including valvular heart disease, cardiomyopathy, arrhythmia, congenital heart disease, hypertrophy syndrome). Liver and kidney failure. Pregnancy. Patients with life expectancy less than 6 months due to concomitant illness. Under immunosuppressive treatment within 8 weeks of the first screening visit

Design outcomes

Primary

MeasureTime frame
IL-1. Timepoint: Day 0 and day 90 after receiving the drug. Method of measurement: ELISA and PCR.;CCL2. Timepoint: Day 0 and day 90 after receiving the drug. Method of measurement: ELISA and PCR.;CXCL8. Timepoint: Day 0 and day 90 after receiving the drug. Method of measurement: ELISA and PCR.;IL-6. Timepoint: Day 0 and day 90 after receiving the drug. Method of measurement: ELISA and PCR.;IL-18. Timepoint: Day 0 and day 90 after receiving the drug. Method of measurement: ELISA and PCR.;IFN-?. Timepoint: Day 0 and day 90 after receiving the drug. Method of measurement: ELISA and PCR.;TNF-a. Timepoint: Day 0 and day 90 after receiving the drug. Method of measurement: ELISA and PCR.—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Hazrati

Tabriz University of Medical Sciences

alihazrati833@gmail.com+98 41 3638 7391

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026